Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 3/20 | 0.39 |
| ▸ | HTR1D | P28221 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14075749 | 0.91 | KDM4E (0.42) | KDM4EKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL14281437 | 0.81 | LMNA (0.44) | KDM4EKMT2AMEN1LMNAGAA | |
| SCHEMBL16450485 | 0.80 | KDM4E (0.49) | KDM4EALDH1A1LMNATDP1GAA | |
| SCHEMBL14075747 | 0.79 | KDM4E (0.49) | KDM4EKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL14536662 | 0.79 | PLAU (0.47) | KDM4EKMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL6421389 | 0.79 | TSHR (0.46) | KMT2AMEN1LMNAGAAL3MBTL1 | |
| SCHEMBL18591537 | 0.78 | ALDH1A1 (0.59) | KDM4EKMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL10497611 | 0.78 | SMPD1 (0.48) | ALDH1A1L3MBTL1TSHR | |
| SCHEMBL14511274 | 0.77 | ALDH1A1 (0.51) | KDM4EALDH1A1LMNATDP1GAA | |
| SCHEMBL10497889 | 0.77 | SMPD1 (0.50) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080213187-A1 | NOVEL CASCADE POLYMER COMPLEXES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | EPIX PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-7211241-B2 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080213187-A1 | NOVEL CASCADE POLYMER COMPLEXES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PGF, F13A1, F11 | KDM4E 4472/4885KMT2A 3253/4885MEN1 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.